2022中国临床医学研究发展报告

本报告分析了2021年度国内外临床医学研究现状与趋势，总结了国内外临床医学研究相关的政策与法规，展示了中国临床医学研究的重要进展与成果，围绕“抑郁症的发病机制、临床诊疗和药物研发进展”这一主题浅析了国际临床医学研究的年度热点。本书延续了之前报告的框架，分为四个章节，以文字、数据、图表相结合的方式，展示了2021年度我国临床医学研究相关情况，可为临床医学研究领域的政策制定者、研究人员、管理工作者、医疗工作者、产品开发人员、以及关心中国医学科技发展的社会各界人士提供参考。

中国生物技术发展中心主要开展我国生物技术领域的战略研究和政策分析，参与国家科技规划的制定，承担科技计划项目的专业化管理，承担生物资源与生物安全管理的有关工作，推动成果转化和产业化，促进国际交流与合作。

目 录 第一章　临床医学研究现状与趋势 ··························································1 一、国际临床医学研究发展现状 ····················································1 二、国内临床医学研究发展现状 ··················································20 第二章　 2021年国内外临床医学研究政策与法规 ···································46 一、国际临床医学研究政策与法规 ···············································46 二、国内临床医学研究政策与法规 ···············································57 第三章　 2021年中国临床医学研究重要成果选编 ···································84 一、重要科学发现 ····································································85 二、新技术新方法 ····································································99 三、临床转化与产品 ································································105 四、临床标准规范与推广 ··························································113 五、学术奖励 ·········································································119 第四章　 2021年临床医学研究热点浅析：抑郁症的发病机制、临床诊疗和药物研发进展 ········································································125 一、抑郁症概述 ······································································125 二、抑郁症发病机制的国内外研究进展 ········································127 三、抑郁症诊疗和药物研发的国内外进展 ·····································142 四、面临的挑战和未来发展方向 ·················································163 图表索引 ···························································································168 附　录 ·······························································································170 附录A　2021年度中国临床医学相关政策文件 ·······························170 附录B　国家临床医学研究中心名录 ············································173 附录C　 中国合格评定国家认可委员会（CNAS）认定的医学实验室 ·······································································175 附录D　美国病理学家协会（CAP）认证的临床检验实验室 ··············194 附录E　2021年度中国企业发起的国际多中心临床试验 ···················202 附录F　2021年度国家药品监督管理局建议审评通过的创新药 ··········214 附录G　2021年度创新医疗器械产品 ···········································221 致　谢 ·······························································································223